Search Result

Results for "

Mlkl-/- NIH-3T3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (2) 5-HT Receptor (1) Akt (8) AMPK (2) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (15) Autophagy (15) BCRP (1) c-Kit (5) c-Met/HGFR (5) Caspase (8) CaSR (2) CDK (2) Collagen (1) DNA-PK (1) Drug Derivative (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (7) Endogenous Metabolite (1) Epigenetic Reader Domain (1) ERK (4) Eukaryotic Initiation Factor (eIF) (2) Farnesyl Transferase (2) Ferroptosis (3) FGFR (5) Fungal (1) Gli (2) Hedgehog (2) Heme Oxygenase (HO) (4) Integrin (1) Interleukin Related (7) Isotope-Labeled Compounds (1) Keap1-Nrf2 (6) Lactate Dehydrogenase (1) Ligands for Target Protein for PROTAC (2) LPL Receptor (1) MDM-2/p53 (2) Mitochondrial Metabolism (1) Mixed Lineage Kinase (38) Necroptosis (24) NF-κB (1) NO Synthase (4) NOD-like Receptor (NLR) (4) P2X Receptor (1) p38 MAPK (6) PANoptosis (1) PARP (3) PDGFR (5) Phosphodiesterase (PDE) (1) PI3K (3) PROTACs (5) Protein Prenyltransferase (1) Pyroptosis (4) Raf (6) Ras (4) Reactive Oxygen Species (ROS) (3) Reference Standards (9) RET (5) RIP kinase (24) ROCK (1) ROS Kinase (1) Small Interfering RNA (siRNA) (3) Smo (2) Src (1) STAT (4) STING (2) TGF-beta/Smad (4) TGF-β Receptor (2) Tie (5) TNF Receptor (5) Topoisomerase (2) Trk Receptor (1) VEGFR (10)
By Research Areas:	Cancer (60) Cardiovascular Disease (9) Endocrinology (6) Infection (2) Inflammation/Immunology (30) Metabolic Disease (12) Neurological Disease (15)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

100

Inhibitors & Agonists

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10331

Regorafenib 85+ Cited Publications BAY 73-4506	VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie	Cancer
Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .

HY-10261

Afatinib 100+ Cited Publications BIBW 2992	EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK	Cancer
Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC₅₀ values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR ^wt, EGFR ^L858R, EGFR ^L858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .

HY-100573

Necrosulfonamide Maximum Cited Publications 139 Publications Verification	Mixed Lineage Kinase Necroptosis Pyroptosis Caspase NOD-like Receptor (NLR) Keap1-Nrf2 TNF Receptor Interleukin Related NO Synthase Heme Oxygenase (HO)	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
Necrosulfonamide is a *MLKL* and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways .

HY-10261A

Afatinib dimaleate 100+ Cited Publications BIBW 2992MA2	EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK	Cancer
Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC₅₀ values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR ^wt, EGFR ^L858R, EGFR ^L858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .

HY-112292

GW806742X 20+ Cited Publications	Mixed Lineage Kinase VEGFR	Others
GW806742X, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a K_d of 9.3 μM. GW806742X has activity against VEGFR2 (IC₅₀=2 nM). GW806742X retards MLKL membrane translocation and inhibits necroptosis .

HY-101524

TC13172 3 Publications Verification	Mixed Lineage Kinase	Cancer
TC13172 is a mixed lineage kinase domain-like protein (MLKL) inhibitor with an EC₅₀ value of 2 nM for HT-29 cells .

HY-N2909

Aurantiamide	NF-κB RIP kinase Mixed Lineage Kinase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Aurantiamide is a non-covalent, orally active, blood-brain-permeable GRPR selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as *RIPK3/MLKL* signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models .

HY-10331A

Regorafenib monohydrate 85+ Cited Publications BAY 73-4506 monohydrate	VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie	Cancer
Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .

HY-144828

*RIP1/RIP3/MLKL* activator 1** 5+ Cited Publications	RIP kinase Mixed Lineage Kinase Necroptosis	Cancer
RIP1/RIP3/MLKL activator 1 (Compound 6i) is a potent anti-glioma agent. RIP1/RIP3/MLKL activator 1 induces necroptosis through *RIP1/RIP3/MLKL* pathway. RIP1/RIP3/MLKL activator 1 exerts acceptable BBB permeability .

HY-N0546

Ligustroflavone 2 Publications Verification Nuezhenoside	CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad	Cardiovascular Disease Neurological Disease Metabolic Disease Endocrinology
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the *RIPK1/RIPK3/MLKL* pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .

HY-145574

Iruplinalkib WX-0593	Anaplastic lymphoma kinase (ALK) ROS Kinase BCRP Akt ERK STAT	Cancer
Iruplinalkib (WX-0593) is an orally active and selective ALK/ROS1 inhibitor. Iruplinalkib can effectively inhibit tyrosine autophosphorylation of ALK and mutant ALK, EGFR, with the IC₅₀ between 5.38 and 16.74 nM. Iruplinalkib is also a suppressive agent of the transporter MATE1, MATE2K, P-gp and BCRP. Iruplinalkib can be used in the study of non-small cell lung cancer .

HY-N0660

Jujuboside B	Apoptosis PARP Caspase AMPK Autophagy VEGFR Keap1-Nrf2 STING 11β-HSD Ferroptosis PI3K Akt p38 MAPK ERK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the *RIPK1/RIPK3/MLKL* pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes .

HY-156591

*PROTAC MLKL* Degrader-1**	PROTACs Mixed Lineage Kinase Necroptosis	Others
PROTAC MLKL Degrader-1 is a selective MLKL PROTAC degrader with a DC₅₀ of 2.4 μM. PROTAC MLKL Degrader-1 blocks necroptosis without modulating the phosphorylation of RIPK1 or RIPK3, and exhibits a linear correlation between *MLKL* levels and necroptotic cell death .

HY-161247

5-HT2A antagonist 2	5-HT Receptor	Metabolic Disease
5HT2A antagonist 2 is an orally active, selective antagonist for 5HT_2A with IC₅₀ of 14 nM. 5-HT2A antagonist 2 exhibits good chemical, hepatocyte, and plasma stability, without significant cytotoxicity in cell lines VERO, HFL-1, L929, NIH3T3, CHO-K1 .

HY-24504

MBA-m1	Mixed Lineage Kinase	Inflammation/Immunology Cancer
MBA-m1 is a *MLKL* inhibitor. MBA-m1 inhibits necroptosis in Mlkl ^−/− NIH-3T3 cells. MBA-m1 ameliorates disease in MLKL-induced dermatitis and abdominal aortic aneurysm mouse model .

HY-137191

CH7233163	EGFR	Cancer
CH7233163 is a noncovalent ATP-competitive inhibitor for EGFR-Del19/T790M/C797S. CH7233163 can overcome Osimertinib (HY-15772)-Resistant EGFR-Del19/T790M/C797S mutation. CH7233163 blocks the EGFR phosphorylation in the Del19/T790M/C797S_NIH3T3 cells. CH7233163 has antitumor activities .

HY-108636

RETRA	MDM-2/p53 RIP kinase Mixed Lineage Kinase Reactive Oxygen Species (ROS) Necroptosis	Cancer
RETRA is a *RIPK1/RIPK3/MLKL* and p73 activator. RETRA mediates plasma membrane disruption, induces ROS accumulation, triggers early mitochondrial hyperpolarization, and synergistically drives necroptosis. RETRA inhibits cancer cells carrying mutant p53 via a p73-dependent salvage pathway. RETRA can be used in research related to cervical cancer and cancers with mutant p53 .

HY-151976

STAT3-IN-15 1 Publications Verification	STAT	Inflammation/Immunology
STAT3-IN-15 is a potent and orally active STAT3 inhibitor against idiopathic pulmonary fibrosis (IPF). STAT3-IN-15 inhibits STAT3 phosphorylation. STAT3-IN-15 also inhibits the migration and deformation of epithelial cells induced by TGF-β1 and inhibit epithelial-mesenchymal transition (EMT) .

HY-100573A

(E/Z)-Necrosulfonamide 1 Publications Verification	Mixed Lineage Kinase Necroptosis Pyroptosis Caspase NOD-like Receptor (NLR) Keap1-Nrf2 TNF Receptor Interleukin Related NO Synthase Heme Oxygenase (HO)	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
(E/Z)-Necrosulfonamide is a racemic compound of Necrosulfonamide (HY-100573). Necrosulfonamide is a *MLKL* and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.

HY-177119

ZBP1 Covalent PROTAC-1	PROTACs RIP kinase Mixed Lineage Kinase	Infection Inflammation/Immunology
ZBP1 Covalent PROTAC-1 is a covalent Z-DNA binding protein 1 ZBP1 PROTAC degrader, with its DC₅₀ being 25.69 nM. ZBP1 Covalent PROTAC-1 integrates the ligand that recruits the VHL E3 ubiquitin ligase and the DNA aptamer (Aptamer Z3) with the specific Zα domain that can bind to ZBP1, which has a high affinity (K_D = 2.71 nM) with ZBP1. After degrading ZBP1, the phosphorylation levels of downstream signaling molecules RIPK3 and MLKL significantly decrease. ZBP1 Covalent PROTAC-1, encapsulated by nano-liposomes, significantly improves the survival rate of mice infected with influenza A virus (IAV) after administration via the trachea .

HY-156119

MLKL-IN-6	Mixed Lineage Kinase Necroptosis	Metabolic Disease Cancer
MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor targeting Mixed Lineage Kinase domain-like (MLKL). MLKL-IN-6 inhibits cell necrosis. MLKL-IN-6 inhibits MLKL phosphorylation and oligomerization during cell necrosis, inhibits immune cell death, and reduces the expression of adhesion factors. MLKL-IN-6 has low cytotoxicity, and it inhibits hepatic stellate cell activation, reduces liver fibrosis marker levels, and has anti-fibrotic effects .

HY-141889

MLKL-IN-2	Mixed Lineage Kinase	Inflammation/Immunology
MLKL-IN-2 is a *MLKL* inhibitor extracted from patent WO2021224505A1, compound (i) .

HY-162424

*ZBP1/RIP3/MLKL* activator 1**	RIP kinase Mixed Lineage Kinase Necroptosis	Cancer
ZBP1/RIP3/MLKL activator 1 (compound 3a) is a synthetically derived quinoline compound. ZBP1/RIP3/MLKL Activator 1 induces DNA damage, enhances intracellular levels of reactive oxygen species (ROS), and triggers apoptosis via the caspase pathway. Furthermore, when apoptosis is inhibited, ZBP1/RIP3/MLKL Activator 1 promotes necroptotic cell death through the ZBP1-RIP3-MLKL pathway. ZBP1/RIP3/MLKL Activator 1 is utilized in oncological research, particularly in the selective targeting of cells with impaired apoptotic function .

HY-115489

GGTI-286	Ras	Cancer
GGTI-286, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC₅₀=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC₅₀s=2 and >30 μM, respectively). GGTI-286 also potently inhibits oncogenic K-Ras4B stimulation with an IC₅₀ of 1 μM .

HY-115489A

GGTI-286 TFA	Protein Prenyltransferase	Cancer
GGTI-286 TFA, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC₅₀=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 TFA selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC₅₀s=2 and >30 μM, respectively). GGTI-286 TFA also potently inhibits oncogenic K-Ras4B stimulation with an IC₅₀ of 1 μM .

HY-112292A

GW806742X hydrochloride 20+ Cited Publications	Mixed Lineage Kinase VEGFR	Cancer
GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a K_d of 9.3 μM. GW806742X hydrochloride has activity against VEGFR2 (IC₅₀=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis .

HY-124429

FQI1	ERK	Cancer
FQI1 is a Late SV40 Factor (LSF) inhibitor. FQI1 inhibits cell proliferation, with IC₅₀s of 3, 0.79, 6.3 μM for NIH/3T3, HeLa, A549 cells. FQI1 can be used for cancer research .

HY-178821

ROCK2-IN-12	ROCK TGF-beta/Smad STAT	Inflammation/Immunology
ROCK2-IN-12 (Compound A25) is a selective ROCK2 inhibitor with an IC₅₀ of 7.0  nM for ROCK2 over ROCK1. ROCK2-IN-12 has potent antifibrotic effects via the TGF-β/Smad and ROCK2/STAT3 signaling pathways. ROCK2-IN-12 significantly reduces collagen deposition and reverses fibrotic progression in Bleomycin (HY-108345)-induced pulmonary fibrosis (PF) mouse models. ROCK2-IN-12 can be used for lung diseases like pulmonary fibrosis research .

HY-16124

Canfosfamide TLK-286; TER286	DNA-PK Apoptosis	Cancer
Canfosfamide (TLK-286, TER286) is a glutathione analogue prodrug that is activated by glutathione S-transferase P1-1 and induces apoptosis. Canfosfamide also inhibits the catalytic kinase activity of DNA-dependent protein kinase (DNA-PK). Canfosfamide produces an anticancer alkylating agent and a glutathione derivative after activation. Canfosfamide can be used to research malignancies .

HY-N3007A

(E)-Naringenin chalcone	Others	Inflammation/Immunology
(E)-Naringenin chalcone is an orally active anti-allergic agent. (E)-Naringenin chalcone also has antioxidant, anti-inflammatory activities. (E)-Naringenin chalcone can improve adipocyte functions. (E)-Naringenin chalcone inhibits histamine release from rat peritoneal mast cell .

HY-148767

MLKL-IN-5	Mixed Lineage Kinase	Others
MLKL-IN-5 is a potent *MLKL* inhibitor that mediates necroptosis .

HY-108960

PPADS	P2X Receptor Interleukin Related	Neurological Disease
PPADS is a P2X receptor (P2X Receptor) antagonist and a reversible competitive antagonist of NAADP receptors, with IC₅₀ values of 68 nM (P2X1) and 214 nM (P2X3), respectively. PPADS alleviates pain-related behaviors in the central and peripheral nervous systems of mice after peripheral neuropathy, inhibits the overproduction of IL-1β, IL-6, iNOS and nNOS, and suppresses the hydrolytic activity of extracellular ATPase. PPADS blocks ATP-mediated inward currents on recombinant rat P2X₁ and P2X₃ receptors, and inhibits purinergic nerve stimulation-induced contraction of rabbit bladder detrusor muscle. PPADS is applicable to research related to neuropathic pain .

HY-149393

RIPK3-IN-3	Mixed Lineage Kinase RIP kinase	Cancer
RIPK3-IN-3 (compound 20) is a selective inhibitor of RIP kinase RIPK3 (IC₅₀=10 nM). RIPK3 mediates the phosphorylation of Mixed Lineage Kinase (MLKL) and causes necroptosis, while RIPK3-IN-3 inhibits p-MLKL oligomerization and thereby inhibits necroptosis. RIPK3-IN-3 also downregulates CXCL5 secretion and inhibits AsPC-1 cell migration and invasion .

HY-148365

NecroIr1	Mixed Lineage Kinase RIP kinase CDK	Cancer
NecroIr1 is an iridium(III) complex, serves as necroptosis inducers in Cisplatin (HY-17394)-resistant lung cancer cells (A549R). NecroIr1 selectively accumulates in mitochondria, leading to oxidative stress and loss of mitochondrial membrane potential (MMP). NecroIr1 activates receptor-interacting serine-threonine kinase 3 (RIPK3) and Mixed Lineage Kinase (MLKL), and regulates CDK4 expression .

HY-148366

NecroIr2	Mixed Lineage Kinase RIP kinase CDK	Cancer
NecroIr2 is an iridium(III) complex, serves as necroptosis inducers in Cisplatin (HY-17394)-resistant lung cancer cells (A549R). NecroIr2 selectively accumulates in mitochondria, leading to oxidative stress and loss of mitochondrial membrane potential (MMP). NecroIr2 activates receptor-interacting serine-threonine kinase 3 (RIPK3) and mixed lineage kinase domain-like pseudokinase (MLKL), and regulates CDK4 expression .

HY-100573S

Necrosulfonamide-d4	Isotope-Labeled Compounds Mixed Lineage Kinase Necroptosis Pyroptosis Caspase NOD-like Receptor (NLR) Keap1-Nrf2 TNF Receptor Integrin NO Synthase Heme Oxygenase (HO)	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
Necrosulfonamide-d₄ is the deuterium labeled Necrosulfonamide (HY-100573). Necrosulfonamide is a *MLKL* and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.

HY-10261R

Afatinib (Standard) BIBW 2992 (Standard)	Reference Standards EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK	Cancer
Afatinib (Standard) is the analytical standard of Afatinib. This product is intended for research and analytical applications. Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .

HY-12316R

20(S)-Hydroxycholesterol (Standard) 3 Publications Verification 20α-Hydroxycholesterol (Standard)	Reference Standards Smo Endogenous Metabolite	Cancer
20(S)-Hydroxycholesterol (Standard) is the analytical standard of 20(S)-Hydroxycholesterol. This product is intended for research and analytical applications. 20(S)-hydroxyCholesterol (20α-Hydroxycholesterol) is an allosteric activator of the oncoprotein smoothened (Smo) that activates the hedgehog (Hh) signaling pathway with an EC₅₀ of 3 μM in a gene transcription reporter assay using NIH3T3 cells .

HY-16906

T338C Src-IN-2	Src	Cancer
T338C Src-IN-2 is a mutant c-Src kinase inhibitor, with an IC₅₀ of 317 nM against T338C c-Src, 57 nM against T338C/V323A c-Src, and 19 nM against T338C/V323S c-Src. T338C Src-IN-2 inhibits the kinase activity of endogenous cysteine gatekeeper MOK. T338C Src-IN-2 reduces global phosphotyrosine levels in v-Src-ES1-transformed NIH-3T3 cells .

HY-152472

ENT-C225	Trk Receptor	Neurological Disease
ENT-C225 is an effective activator of TrkB neurotrophin receptor. ENT-C225 has high effect on activating TrkB receptor (TrkBR), and has good physicochemical properties and neuroprotective properties .

HY-129767

CMLD012612	Eukaryotic Initiation Factor (eIF)	Cancer
CMLD012612 is an amidino-rocaglate containing a hydroxamate group and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012612 inhibits cell translation and is cytotoxic to NIH/3T3 cells with an IC₅₀ value of 2 nM. CMLD012612 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A) and possesses potent anti-neoplastic activity .

HY-173185

RIP1-IN-1	RIP kinase Necroptosis	Inflammation/Immunology
RIP1-IN-1 is an orally active RIP1 inhibitor with strong RIP1 binding affinity (K_d: 110 nM). RIP1-IN-1 exhibits strong anti-necroptosis activity. RIP1-IN-1 effectively inhibits the formation of necrosomes by blocking the phosphorylation of RIP1, RIP3 and MLKL signaling pathways. RIP1-IN-1 inhibits necroptosis and can be used in the study of acute liver injury .

HY-128041

alpha-Hydroxy farnesyl phosphonic acid Hydroxyfarnesyl phosphate	Farnesyl Transferase	Others
α-hydroxy Farnesyl phosphonic acid is a nonhydrolyzable analog of farnesyl pyrophosphate which acts as a competitive inhibitor of farnesyl transferase (FTase). At concentrations greater than 1 μM, α-hydroxy farnesyl phosphonic acid inhibits the processing of Ras in Ha-ras-transformed NIH3T3 cells.

HY-151542

MLKL-IN-4	Mixed Lineage Kinase Necroptosis RIP kinase	Neurological Disease
MLKL-IN-4 (compound 56) is a potent *MLKL* (Mixed lineage kinase domain-like protein) inhibitor. MLKL-IN-4 inhibits necroptosis in HT-29 cells and acts downstream of MLKL phosphorylation, with EC₅₀ of 82 nM . MLKL-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-151541

MLKL-IN-3	Mixed Lineage Kinase Necroptosis	Neurological Disease
MLKL-IN-3 (compound 66) is a potent *MLKL* (Mixed lineage kinase domain-like protein) inhibitor. MLKL-IN-3 inhibits necroptosis in HT-29 cells and acts downstream of MLKL phosphorylation, with EC₅₀ of 31 nM . MLKL-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-178163

Zharp1-163	Ferroptosis Necroptosis RIP kinase Reactive Oxygen Species (ROS) Mixed Lineage Kinase	Inflammation/Immunology
Zharp1-163 is a dual inhibitor of ferroptosis and necroptosis. Zharp1-163 effectively blocks ferroptosis by reducing reactive oxygen species (ROS) levels and inhibits necroptosis by potently and selectively targeting RIPK1 kinase activity (K_D = 240 nM; IC₅₀ = 406.1 nM). Zharp1-163 inhibits the cellular activation of RIPK1, RIPK3 and *MLKL* in response to necroptotic stimulation. Zharp1-163 markedly attenuates TNF-α (HY-P1875)-induced systemic inflammatory syndrome, including the prevention of TNF-α-induced mortality and hypothermia in mice. Zharp1-163 significantly alleviates acute kidney injury associated with both necroptosis and ferroptosis in models induced by Cisplatin (HY-17394) and ischemia-reperfusion. Zharp1-163 can be used for the study of diseases associated with cell death pathways, such as kidney disease .

HY-169072

*PROTAC MLKL* Degrader-2**	PROTACs Mixed Lineage Kinase	Cancer
PROTAC MLKL Degrader-2 (compound MP-1) is a PROTAC targeting *MLKL* (Mixed Lineage Kinase). PROTAC *MLKL* Degrader-2 is composed of PROTAC target protein ligand PROTAC *MLKL* Degrader-2 (HY-169072) (red part), E3 ligase ligand Thalidomide (HY-14658) (blue part) and PROTAC Linker N-Methylpiperazine (HY-78871) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is Thalidomide-N-methylpiperazine (HY-169074) ^{[1] ^.}

HY-144437

ALK5-IN-9	TGF-β Receptor	Cancer
ALK5-IN-9 (Compound 8h) is a potent and orally active inhibitor of TGFβRI (ALK5). ALK5-IN-9 inhibits ALK5 autophosphorylation and NIH3T3 cell activity with IC₅₀ values of 25 nM and 74.6 nM, respectively. ALK5-IN-9 also shows favorable pharmacokinetic profile and ameliorated hERG inhibition. ALK5-IN-9 has the potential for the research of cancer disease .

HY-117807

A-176120	Ras Farnesyl Transferase VEGFR	Cancer
A-176120 is a selective inhibitor of farnesyl transferase (IC₅₀=1.2 nM) based on a farnesyl pyrophosphate (FPP) analog, with superior selectivity against GGTaseI (IC₅₀=423 nM), GGTaseII (IC₅₀=3000 nM), and SSase (IC₅₀>10 μM). A-176120 inhibits ras processing in H-ras transformed NIH3T3 cells and HCT116 K-ras mutant cells (ED₅₀=1.6 and 0.5 μM, respectively). A-176120 has antiangiogenic and antitumor activities in vivo and reduces capillary structure formation and VEGF secretion .

HY-161921

Antifungal agent 108	Fungal	Infection
Antifungal agent 108 (compound 14d), an original imidazo[1,2-b]pyridazine derivative, shows potent antifungal activity against Madurella mycetomatis (MM55 strain) with an IC₅₀ of 0.9 μM. Antifungal agent 108 exhibits an IC₅₀ of 14.3 μM on cell viability of NIH-3T3 murine fibroblast .

Cat. No.	Product Name	Target	Research Area

HY-P11609

TGFβ1-IN-4	TGF-beta/Smad	Metabolic Disease
TGFβ1-IN-4 is a TGF-β1 inhibitor. TGFβ1-IN-4 inhibits myofibroblast activation and epithelial-mesenchymal transition in vitro. TGFβ1-IN-4 alleviates renal fibrosis in a mouse model of renal fibrosis. TGFβ1-IN-4 can be used for research on fibrotic diseases such as renal fibrosis .

Cat. No.	Product Name

HY-K2014

PEI Transfection Reagent

50+ Cited Publications

MCE PEI Transfection Reagent is designed based on 25 kDa PEI. It has high-efficiency, low-toxicity, strong-stability, and is suitable for many cell types, such as HEK-293、HEK-293T、CHO-K1、COS-1、COS-7、NIH/3T3、Sf9、HepG2 and HeLa et, even some hard-to-transfect cells. It can also be applied to large-scale recombinant protein expression and virus production. The 1 mL is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

Cat. No.	Product Name	Target	Research Area	Image

HY-P991226

RG7287	Inhibitory Antibodies	Cancer
RG7287 is an activating antibody inhibitor targeting human CDCP1. RG7287 prevents the loss of contact inhibition caused by the co-transformation of NIH3T3 cells with CDCP1 and Src in focus formation assays. RG7287 inhibits tumor cell proliferation and leads to a significant reduction in CDCP1 levels .

HY-P991966

Anti-Human/Mouse EGFR Antibody (7A7)	EGFR	Cancer
Anti-Human/Mouse EGFR Antibody (7A7) ia an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab. Anti-Human/Mouse EGFR Antibody (7A7) fails to induce tumor regression in the HPV38 tumor model where EGFR is not expressed in mice. Anti-Human/Mouse EGFR Antibody (7A7) can be used in EGFR-expressing HPV38 tumor-related studies .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2909

Aurantiamide	Alkaloids Classification of Application Fields Other Alkaloids Umbelliferae Plants Inflammation/Immunology Disease Research Fields Carphephorus corymbosus (Nutt.) Torr. & A.Gray Source Classification	NF-κB RIP kinase Mixed Lineage Kinase
Aurantiamide is a non-covalent, orally active, blood-brain-permeable GRPR selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as *RIPK3/MLKL* signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models .

HY-N0546

Ligustroflavone 2 Publications Verification Nuezhenoside	Flavonoids Oleaceae Classification of Application Fields Flavones Ligustrum lucidum Ait. Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Source Classification	CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the *RIPK1/RIPK3/MLKL* pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .

HY-N0660

Jujuboside B	Cardiovascular Disease Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification	Apoptosis PARP Caspase AMPK Autophagy VEGFR Keap1-Nrf2 STING 11β-HSD Ferroptosis PI3K Akt p38 MAPK ERK
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the *RIPK1/RIPK3/MLKL* pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes .

HY-N3007A

(E)-Naringenin chalcone	Phenols Polyphenols Solanum lycopersicum L. Solanaceae Plants	Others
(E)-Naringenin chalcone is an orally active anti-allergic agent. (E)-Naringenin chalcone also has antioxidant, anti-inflammatory activities. (E)-Naringenin chalcone can improve adipocyte functions. (E)-Naringenin chalcone inhibits histamine release from rat peritoneal mast cell .

HY-12316R

20(S)-Hydroxycholesterol (Standard) 3 Publications Verification 20α-Hydroxycholesterol (Standard)	Classification of Application Fields Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	Reference Standards Smo Endogenous Metabolite
20(S)-Hydroxycholesterol (Standard) is the analytical standard of 20(S)-Hydroxycholesterol. This product is intended for research and analytical applications. 20(S)-hydroxyCholesterol (20α-Hydroxycholesterol) is an allosteric activator of the oncoprotein smoothened (Smo) that activates the hedgehog (Hh) signaling pathway with an EC₅₀ of 3 μM in a gene transcription reporter assay using NIH3T3 cells .

HY-N0546R

Ligustroflavone (Standard) Nuezhenoside (Standard)	Structural Classification Flavonoids Oleaceae Flavones Ligustrum lucidum Ait. Phenols Polyphenols Plants Source Classification	Reference Standards CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad
Ligustroflavone (Standard) is the analytical standard of Ligustroflavone (HY-N0546). This product is intended for research and analytical applications. Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the *RIPK1/RIPK3/MLKL* pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .

HY-N17906

Bletimalate C	Bletilla striata (Thunb. ex Murray) Rchb. f. Structural Classification Natural Products Orchidaceae Plants Source Classification	Collagen
Bletimalate C is a 2-isobutyl malate ester present in the tubers of Bletilla striata. Bletimalate C potently inhibits the production of total Collagen in TGF-β1-activated NIH/3T3 cells, with an IC₅₀ of 22.16 μM. Bletimalate C can be used for the research of pulmonary fibrosis .

HY-N8380

(-)-Latifolin	Dalbergia hupeana Hance Phenols Polyphenols Plants Source Classification Fabaceae	Apoptosis Autophagy PI3K Necroptosis
(-)-Latifolin, a flavonoid, induces apoptotic cell death by targeting PI3K/AKT/mTOR/p70S6K signaling. (-)-Latifolin significantly inhibits the cell proliferation of oral squamous cell carcinoma (OSCC), and causes the anti-metastatic activities by effectively blocking cell migration, invasion, and adhesion via the inactivation of FAK/Src. (-)-Latifolin suppresses autophagic-related proteins and autophagosome formation. (-)-Latifolin inhibits necroptosis by dephosphorylating necroptosis-regulatory proteins (RIP1, RIP3, and MLKL). (-)-Latifolin has beneficial effects on anti-aging, anti-carcinogenic, anti-inflammatory, and cardio-protective activities .

HY-N18020

Saurufuran A	Structural Classification Saururaceae Saururus chinensis (Lour.) Baill. Ketones, Aldehydes, Acids Plants Source Classification	Others
Saurufuran A is a PPARγ agonist with an EC₅₀ of 16.7 μM. Saurufuran A is applicable to research related to type 2 diabetes, inflammatory diseases and certain cancers .

HY-N0660R

Jujuboside B (Standard)	Triterpenes Structural Classification other families Terpenoids Plants Source Classification	Reference Standards ERK p38 MAPK Akt PI3K 11β-HSD STING VEGFR Ferroptosis Autophagy Apoptosis Keap1-Nrf2 Caspase PARP AMPK
Jujuboside B (Standard) is the analytical standard of Jujuboside B. This product is intended for research and analytical applications. Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the *RIPK1/RIPK3/MLKL* pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes.

HY-N18339

Camaroside	Apocynaceae Structural Classification Flavonoids Flavones Calotropis procera (Aiton) W. T. Aiton Plants Source Classification	Drug Derivative
Camaroside is a flavonoid glycoside with weak cytotoxic activity against cancer cells and fibroblasts, and no significant antimicrobial activity. Camaroside reduces metabolic activity of fibroblasts and liver cancer cells.C amaroside can be found in the vegetative stems of Calotropis procera .

Species:	Human (2)
Tag:	His (2) GST (1)
Source:	sf9 insect cells (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702574

	MLKL Protein, Human (His) 3 Publications Verification hMlkl; Mixed lineage kinase domain like	Human	E. coli
	MLKL protein is a pseudokinase that plays a key role in TNF-induced necroptosis. Despite lacking intrinsic kinase activity, it is activated through RIPK3 phosphorylation, leading to homotrimerization, plasma membrane localization, and execution of necroptosis. MLKL Protein, Human (His) is the recombinant human-derived MLKL protein, expressed by E. coli , with N-6*His labeled tag.

HY-P705851

	MLKL Protein, Human (sf9, His-GST) hMlkl; Mixed lineage kinase domain like	Human	sf9 insect cells

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-100573S

Necrosulfonamide-d4

Necrosulfonamide-d₄ is the deuterium labeled Necrosulfonamide (HY-100573). Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.

Host:	Mouse (1) Rabbit (5)
Reactivity:	Human (5) Rat (2) Mouse (4)
Application:	IHC-P (5) ICC/IF (3) IP (1) WB (5) ELISA (2)
Isotype:	IgG, Kappa (1) IgG (4)
Conjugation:	Non-conjugated (6)
Clonality:	Monoclonal (6) Recombinant (4)
Modification:	Phosphorylated (4) Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P81878

	*Phospho-MLKL* (Ser358) Antibody (YA1623)** 5 Publications Verification Mlkl	WB, IHC-P	Human
	Phospho-MLKL (Ser358) Antibody (YA1623) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-MLKL (Ser358).

HY-P86069

	*Phospho-MLKL(S358) Antibody (YA5761)* Mlkl	ICC/IF, IHC-P	Human
	Phospho-MLKL(S358) Antibody (YA5761) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Phospho-MLKL(S358).

HY-P86228

	MLKL Antibody (YA5920) Mlkl; Mixed lineage kinase domain-like protein	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	MLKL Antibody (YA5920) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MLKL.

HY-P80227

	MLKL Antibody (YA289) 2 Publications Verification	WB, IHC-P	Human, Mouse
	MLKL Antibody (YA289) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MLKL.

HY-P80468

	*Phospho-MLKL* (Ser345) Antibody (YA174)** 1 Publications Verification	WB, IHC-P	Mouse
	Phospho-MLKL (Ser345) Antibody (YA174) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-MLKL (Ser345).

HY-P87753

	*Phospho-MLKL* (Ser345) Antibody (YA7438)**	WB, ICC/IF, ELISA	Human, Mouse, Rat
	Phospho-MLKL (Ser345) Antibody (YA7438) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to Phospho-MLKL (Ser345).